跳至主要内容
临床试验/NCT04671329
NCT04671329已完成不适用

A Prospective, Multi-site Clinical Study to Collect User Feedback Using Affirm® Contrast Biopsy

Hologic, Inc.4 个研究点 分布在 1 个国家目标入组 67 人开始时间: 2021年3月5日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Hologic, Inc.
入组人数
67
试验地点
4
主要终点
Number of Participants With Technical Success

研究概览

简要总结

Currently, if a radiologist finds a suspicious lesion seen only on a diagnostic Contrast Enhanced Digital Mammography (CEDM) exam requiring biopsy the biopsy procedure would likely be performed with MRI guidance because there are currently limited solutions to biopsy with CEDM guidance. Affirm Contrast Biopsy will provide an additional solution to biopsy/localize lesions found by using a CEDM imaging modality.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
40 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Females aged 40 years of age or older recommended for biopsy who have had a suspicious finding on previous contrast enhanced imaging or have lesions that may be occult under other modalities
  • Subject is able to read, understand, and sign the study specific informed consent form after the nature of the study has been fully explained to them

排除标准

  • Subjects who require a Legally Authorized Representative (LAR) for Informed Consent
  • Subjects who, based on the physician's judgement, may be at increased risk for complications associated with renal function, anticoagulant therapy, or bleeding disorders
  • Subjects who have had a previous allergic reaction to IV contrast agent

结局指标

主要结局

Number of Participants With Technical Success

时间窗: Up to 1h (time to complete the procedure)

Technical success was defined as successfully completing the breast biopsy procedure with the Affirm Contrast Biopsy system for each participant (60 participants equals 60 procedures).

次要结局

未报告次要终点

研究者

发起方
Hologic, Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验